[go: up one dir, main page]

UA108277C2 - Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production - Google Patents

Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production

Info

Publication number
UA108277C2
UA108277C2 UAA201307936A UAA201307936A UA108277C2 UA 108277 C2 UA108277 C2 UA 108277C2 UA A201307936 A UAA201307936 A UA A201307936A UA A201307936 A UAA201307936 A UA A201307936A UA 108277 C2 UA108277 C2 UA 108277C2
Authority
UA
Ukraine
Prior art keywords
valsartan
lercanidipine hydrochloride
production
preparation containing
complex preparation
Prior art date
Application number
UAA201307936A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Юн Сік Чун
Су Ах Парк
Ре Сунь Кім
Сун Іл Кім
Цзе Хьон Цзюн
Дун Ку Кім
Йо Рін Кім
Хі Дун Парк
Сеон Цзе Парк
Сунь Хак Лі
Цзюй Хун Кім
Мінь Юнь Цзюн
Original Assignee
Елджі Лайф Саєнсез Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA108277(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Елджі Лайф Саєнсез Лтд. filed Critical Елджі Лайф Саєнсез Лтд.
Publication of UA108277C2 publication Critical patent/UA108277C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising lercanidipine hydrochloride and valsartan as active components and a method for the preparation thereof. The pharmaceutical composition comprising lercanidipine hydro-chloride and valsartan according to the present invention has a superior effect on the prevention and treatment of cardiovascular diseases and their complex diseases, and reduces the adverse effects of each component. In addition, the present composition comprises lercanidipine hydrochloride and valsartan in a separated form so as to increase the dissolution rates of both components and reduce the adverse effects.
UAA201307936A 2010-12-09 2011-12-07 Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production UA108277C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
UA108277C2 true UA108277C2 (en) 2015-04-10

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201307936A UA108277C2 (en) 2010-12-09 2011-12-07 Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production

Country Status (18)

Country Link
EP (1) EP2648730A4 (en)
KR (1) KR101414814B1 (en)
CN (1) CN103249415B (en)
AR (1) AR084195A1 (en)
AU (1) AU2011339150B2 (en)
BR (1) BR112013013415A2 (en)
CL (1) CL2013001626A1 (en)
CO (1) CO6721030A2 (en)
DO (1) DOP2013000115A (en)
EA (1) EA201390844A1 (en)
IL (1) IL226449A0 (en)
MX (1) MX2013005716A (en)
PE (1) PE20140699A1 (en)
PH (1) PH12013500980A1 (en)
SG (1) SG190326A1 (en)
UA (1) UA108277C2 (en)
UY (1) UY33772A (en)
WO (1) WO2012077968A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (en) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 Compound preparation of lercanidipine and atorvastatin
MX374223B (en) * 2013-03-12 2025-03-05 Lg Chemical Ltd PREPARATION OF A COMPLEX INCLUDING VALSARTAN AND ROSUVASTATIN CALCIUM AND MANUFACTURING METHOD THEREOF.
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (en) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
BRPI0417043A (en) * 2003-12-01 2007-02-06 Lifecycle Pharma As pharmaceutical composition, solid dosage form, manufacturing method of solid dosage form, and, use of the composition
TWI388345B (en) 2005-06-27 2013-03-11 Sankyo Co Solid dosage form comprising angiotensin iireceptor antagonist and calcium channel blocker for prophylaxis or treatment of hypertension
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.

Also Published As

Publication number Publication date
EP2648730A2 (en) 2013-10-16
MX2013005716A (en) 2013-06-12
EA201390844A1 (en) 2013-11-29
DOP2013000115A (en) 2014-07-31
KR101414814B1 (en) 2014-07-21
AU2011339150B2 (en) 2015-09-10
AR084195A1 (en) 2013-04-24
PH12013500980A1 (en) 2013-07-08
CN103249415B (en) 2017-12-12
PE20140699A1 (en) 2014-06-13
AU2011339150A1 (en) 2013-06-06
CL2013001626A1 (en) 2013-10-04
IL226449A0 (en) 2013-07-31
CN103249415A (en) 2013-08-14
KR20120089787A (en) 2012-08-13
WO2012077968A3 (en) 2012-07-26
EP2648730A4 (en) 2014-08-06
UY33772A (en) 2012-07-31
SG190326A1 (en) 2013-06-28
BR112013013415A2 (en) 2019-09-24
WO2012077968A2 (en) 2012-06-14
CO6721030A2 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
MY173823A (en) Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
IN2012DN03312A (en)
IN2014KN00948A (en)
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
PH12013501143A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
IL219437A (en) Substituted benzamide derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the preparation of a medicament for treating cardiovascular disorders
WO2010092090A3 (en) Novel salts of sitagliptin
WO2011157722A3 (en) Solid ivabradine-containing composition
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2014203275A3 (en) An improved process for the preparation of apixaban and intermediates thereof
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
UA108277C2 (en) Complex preparation containing lercanidipine hydrochloride and valsartan, and method for production
PH12014502836B1 (en) Medicament form for release of active ingredients
WO2011064558A3 (en) Pharmaceutical composition
WO2012155226A8 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
MX2013002261A (en) Substituted n-phenethyltriazoloneacetamides and use thereof.
PH12013502080A1 (en) Modified release pharmaceutical compositions of desvenlafaxine
TN2013000212A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and mathod for the preparation therof
CA2865484A1 (en) Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2013054364A3 (en) Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof
WO2012114352A3 (en) Pharmaceutical compositions of maraviroc and process for the preparation thereof
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet
WO2012060791A3 (en) Production method for pharmaceutical compositions comprising cefdinir